Anish B Parikh, MD

Chief Fellow, Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai. Views are my own.

[Kai Tsao @kai_tsao]

Who get immune mediated adverse events on CPI therapy? @JanieQian @VaibhavPatelMD @anishbparikh @WilliamOhMD @MattGalsky @kai_tsao @TischCancer @IcahnMountSinai

[Kai Tsao @kai_tsao]

What happens to patients with advanced GU cancers treated with immune checkpoint inhibitors at radiographic disease progression?
@VaibhavPatelMD @anishbparikh @WilliamOhMD @MattGalsky @kai_tsao @TischCancer @IcahnMountSinai @JanieQian

[Kai Tsao @kai_tsao]

Predicting toxicity leading to docetaxel discontinuation in prostate cancer-@anishbparikh @albertoma90 @DrJohnSfakianos @WilliamOhMD @MattGalsky @TischCancer

[Anish B Parikh, MD @anishbparikh]

> 25% of hospitalizations for patients with prostate cancer are potentially avoidable https://t.co/JNiD9ubWKO @ASCO @JOP_ASCO @IcahnMountSinai @TischCancer

[Anish B Parikh, MD @anishbparikh]

OCM claims data can be transformed via clinical stratification and appropriate risk adjustment in order to drive value-based cancer care https://t.co/bQRsg58xj7 @JOP_ASCO @ASCO @TischCancer @IcahnMountSinai